Downstream effectors of oncogenic ras in multiple myeloma cells.

Hu, Liping

Downstream effectors of oncogenic ras in multiple myeloma cells. [electronic resource] - Blood Apr 2003 - 3126-35 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

0006-4971

10.1182/blood-2002-08-2640 doi


Alkyl and Aryl Transferases--antagonists & inhibitors
Cell Cycle
Chromones--pharmacology
DNA-Binding Proteins--metabolism
Enzyme Inhibitors--pharmacology
Farnesyltranstransferase
Flavonoids--pharmacology
Genes, ras
I-kappa B Proteins--genetics
Interleukin-6--physiology
MAP Kinase Signaling System--drug effects
Mitogen-Activated Protein Kinase 1--physiology
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinases--physiology
Morpholines--pharmacology
Multiple Myeloma--genetics
NF-kappa B--physiology
Neoplasm Proteins--antagonists & inhibitors
Oncogene Protein p21(ras)--physiology
Phosphatidylinositol 3-Kinases--physiology
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation--drug effects
Protein Kinase Inhibitors
Protein Kinases--physiology
Protein Processing, Post-Translational--drug effects
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins--antagonists & inhibitors
Proto-Oncogene Proteins c-akt
Recombinant Fusion Proteins--physiology
Ribosomal Protein S6 Kinases, 70-kDa--physiology
STAT3 Transcription Factor
Signal Transduction--drug effects
Sirolimus--pharmacology
TOR Serine-Threonine Kinases
Trans-Activators--metabolism
Transfection
Tumor Cells, Cultured--drug effects